“Paper NDAs”
This article was originally published in The Tan Sheet
Executive Summary
Pursuing Rx-to-OTC switches under section 505(b)(2) of Hatch/Waxman patent law is "potentially a very good avenue" for companies to use, Morgan Lewis lawyer Stephen Paul Mahinka says at Regulatory Affairs Professionals Society annual conference in Washington, D.C. Oct. 9. Both Wyeth and McNeil used 505(b)(2) application, or "paper NDA," approach to seek OTC approval for loratadine (Schering-Plough's Claritin) (1"The Tan Sheet" Feb. 4, 2002, p. 3). Mahinka expects "some response" from FDA in next several months on citizen petition filed by Pfizer and Pharmacia in 2001 requesting FDA disallow 505(b)(2) NDAs from relying on innovator's data...
You may also be interested in...
Claritin Patent Infringement Suit Brings Industry Into OTC Antihistamine Fray
Schering-Plough's lawsuits against McNeil Consumer Healthcare and Whitehall-Robins could at least temporarily relieve FDA of having to make a highly charged public policy decision on whether to advocate a forced switch of second-generation antihistamines
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.